Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
Article Date
October 1, 2024
This article is featured on another website.
Go to article
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…